Tyson Foods Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Tyson Foods (NYSE:TSN) reported Q2 sales of $13.13 billion. Earnings fell to a loss of…

Benzinga Pro data, Tyson Foods (NYSE:TSN) reported Q2 sales of $13.13 billion. Earnings fell to a loss of $91.00 million, resulting in a 128.44% decrease from last quarter. In Q1, Tyson Foods earned $320.00 million, and total sales reached $13.26 billion.

What Is Return On Capital Employed?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Tyson Foods posted an ROCE of -0.0%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company’s recent performance, but does not account for factors that could affect earnings and sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Tyson Foods is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Tyson Foods, a negative ROCE ratio of -0.0% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Upcoming Earnings Estimate

Tyson Foods reported Q2 earnings per share at $-0.04/share, which did not meet analyst predictions of $0.8/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in

PRLD